苑东生物(688513) - 2025 Q3 - 季度财报

Financial Performance - The company's revenue for the third quarter was ¥364,685,045.87, a decrease of 1.55% compared to the same period last year[4]. - Total profit for the quarter reached ¥92,352,352.05, representing an increase of 28.42% year-over-year[4]. - Net profit attributable to shareholders was ¥83,590,556.58, up 18.52% from the previous year[4]. - The net profit after deducting non-recurring gains and losses was ¥69,186,088.86, reflecting a growth of 27.85% year-over-year[4]. - Total operating revenue for the first three quarters of 2025 was CNY 1,019,133,615.33, a decrease of 2.8% compared to CNY 1,039,937,156.56 in the same period of 2024[21]. - Net profit for the first three quarters of 2025 was CNY 220,162,482.66, slightly up from CNY 217,023,597.92 in 2024, representing a growth of 1.0%[23]. - The company reported a basic earnings per share of CNY 1.25 for the first three quarters of 2025, compared to CNY 1.24 in 2024[23]. Assets and Liabilities - The company's total assets increased by 4.67% to ¥3,558,922,033.10 compared to the end of the previous year[5]. - Current assets reached RMB 2,075,169,166.49, compared to RMB 1,928,705,677.43 at the end of 2024, indicating an increase of about 7.63%[17]. - Total liabilities stood at RMB 1,186,539,861.36, compared to RMB 1,189,252,367.98 at the end of 2024, showing a slight decrease of about 0.23%[18]. - The total liabilities decreased slightly to CNY 692,940,971.40 from CNY 702,205,924.57 year-over-year[22]. - The total equity attributable to shareholders increased to CNY 2,865,981,061.70, up from CNY 2,697,921,576.03, reflecting a growth of 6.2%[22]. Cash Flow - Cash flow from operating activities for the year-to-date was ¥218,818,190.70, showing a significant increase of 49.21%[10]. - Operating cash flow for the first three quarters of 2025 increased to CNY 218,818,190.70, compared to CNY 146,646,770.03 in the same period of 2024, marking a significant increase of 49.2%[26]. - The company recorded a total cash inflow from operating activities of CNY 1,159,913,582.80, compared to CNY 1,027,032,791.52 in the previous year[26]. - The net cash flow from investing activities was -$586.19 million, compared to -$156.23 million in the previous period, indicating a significant increase in cash outflow[27]. - The net cash flow from financing activities was -$37.61 million, an improvement from -$175.47 million in the previous period[27]. - The company experienced a net decrease in cash and cash equivalents of -$405.18 million, compared to -$185.30 million in the previous period[27]. Research and Development - Research and development expenses totaled ¥62,188,527.85, a decrease of 25.99% compared to the same period last year[5]. - Research and development expenses for the first three quarters of 2025 were CNY 183,301,396.13, a slight decrease from CNY 188,129,351.01 in 2024[22]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 6,482[13]. - The top shareholder, Wang Ying, holds 34.89% of the shares, totaling 61,593,000 shares[13]. - The company has not reported any significant changes in the participation of major shareholders in margin financing or securities lending activities[15]. Other Information - The company recognized non-recurring gains totaling ¥14,404,467.72 for the quarter[8]. - The company will not apply new accounting standards starting from 2025[28].